BALTIMORE, MD – Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, announced today a strategic collaboration with Almac Diagnostic Services, a global stratified medicine company, to enhance opportunities for clinical trial development and companion diagnostic (CDx) projects.
PGDx and Almac Diagnostic Services will focus on providing access to tumor profiling assays for both tissue and plasma samples, specifically, PGDx elio™ tissue complete and PGDx elio™ plasma resolve. This collaboration will combine Almac’s world-class genomics services and expertise in development and delivery of molecular diagnostics with PGDx’s leadership in cancer genomics to accelerate solutions that will deliver precision medicine to more patients.
“We are proud to enter into this strategic collaboration with Almac. Their longstanding reputation for providing high quality lab services to patients worldwide, along with their proven track record of implementing new technologies make this partnership ideal,” said Megan Bailey, CEO, PGDx. “As we continue our quest to empower the fight against cancer, collaborating with Almac will allow us to deliver precision medicine solutions to a broader population and advance innovations in nextgeneration sequencing technology.”
Michael Sloan, Global Vice President of Commercial Operations, Almac Diagnostic Services said: “This collaboration with PGDx will enable Almac to provide our Pharmaceutical and Biotech partners with tissue and liquid biopsy options to support their translational research, clinical trials and CDx development requirements. The assay panels PGDx has developed will allow our clients to access world-class next generation sequencing science and bioinformatics solutions.” About Personal Genome Diagnostics Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome. We are committed to improving clinical insight, speed of results, and healthcare economics by delivering a portfolio of regulated tissue-based and liquid biopsy genomic products for health systems worldwide. PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies. For additional information, visit www.pgdx.com.
About Almac Diagnostic Services
Almac Diagnostic Services is a global stratified medicine company specialising in biomarker driven clinical trials. The company is focused on the discovery, development and commercialisation of diagnostic and companion diagnostic tests. The company partners with biopharma companies to provide solutions ranging from biomarker discovery to CDx development including regulatory submissions and commercialisation. Almac Diagnostic Services also facilitates biomarker clinical trial management and clinical test delivery from its CLIA-accredited labs. The tests developed at Almac Diagnostic Services have a wide range of applications including patient selection and are utilised in phase I to phase III registrational clinical trials. For more information visit: www.almacgroup.com/diagnostics.
About Almac Group
A unique culture delivering exceptional solutions The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture. The international company is a privately owned organization which has grown organically over the past five decades now employing over 5,600 highly skilled personnel across 18 facilities including Europe, the US and Asia. For more information visit: www.almacgroup.com.